ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture.
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.8field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Window-of-Opportunity Study Utilizing Preoperative Cetuximab in Patients with Head and Neck Cancer.Cancer research communications · 2026Article
- Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials.Materials today. Bio · 2024Review
- Prospective Characterization of Circulating Tumor Cell Kinetics in Patients With Oligometastatic Disease Receiving Definitive Intent Radiation Therapy.JCO precision oncology · 2023Article
- Circulating tumor cell abundance in head and neck squamous cell carcinoma decreases with successful chemoradiation and cetuximab treatment.Cancer letters · 2023Article
- Nanotechnology and machine learning enable circulating tumor cells as a reliable biomarker for radiotherapy responses of gastrointestinal cancer patients.Biosensors & bioelectronics · 2023Article
- Flow Rate-Independent Multiscale Liquid Biopsy for Precision Oncology.ACS sensors · 2023Article
- Design of Polymeric Surfaces as Platforms for Streamlined Cancer Diagnostics in Liquid Biopsies.Biosensors · 2023Review
- Factors influencing the diagnostic and prognostic values of circulating tumor cells in breast cancer: a meta-analysis of 8,935 patients.Frontiers in oncology · 2023Review
- Branched, dendritic, and hyperbranched polymers in liquid biopsy device design.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Gold nanoparticles in virus detection: Recent advances and potential considerations for SARS-CoV-2 testing development.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Tri-modal liquid biopsy: Combinational analysis of circulating tumor cells, exosomes, and cell-free DNA using machine learning algorithm.Clinical and translational medicine · 2021Article
- Efficient Capture and Raman Analysis of Circulating Tumor Cells by Nano-Undulated AgNPs-rGO Composite SERS Substrates.Sensors (Basel, Switzerland) · 2020Article
- Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.Biosensors & bioelectronics · 2020Article
- Immunoavidity-Based Capture of Tumor Exosomes Using Poly(amidoamine) Dendrimer Surfaces.Nano letters · 2020Article
- An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy.Nano letters · 2020Article
- Microfluidics and Nanomaterial-based Technologies for Circulating Tumor Cell Isolation and Detection.Sensors (Basel, Switzerland) · 2020Review
- Nanostructured Substrates for Detection and Characterization of Circulating Rare Cells: From Materials Research to Clinical Applications.Advanced materials (Deerfield Beach, Fla.) · 2020Review
- Nanotechnology in Radiation Oncology.Hematology/oncology clinics of North America · 2019Review
- Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.Clinical and experimental medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Ja Hye Myung *Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois, Chicago, Illinois.
Michael J Eblan *Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Joseph M CasterDepartment of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Sin-Jung ParkDepartment of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois, Chicago, Illinois.
Michael J PoellmannPharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, Madison, Wisconsin.
Kyle WangDepartment of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Kevin A TamDepartment of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois, Chicago, Illinois.
Seth M MillerDepartment of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Colette ShenDepartment of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Ronald C ChenDepartment of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Tian ZhangDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, North Carolina.
Joel E TepperDepartment of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0002-8591-4228
Bhishamjit S CheraDepartment of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Andrew Z WangDepartment of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. andrew_wang@med.unc.edu seungpyo.hong@wisc.edu.
Seungpyo HongDepartment of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois, Chicago, Illinois. andrew_wang@med.unc.edu seungpyo.hong@wisc.edu.
University of North Carolina at Chapel Hill · USUniversity of Wisconsin–Madison · USIllinois College · USDuke Medical Center · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5MSmall Animal Imaging CoreU54CA198999 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO · 2015 to 2019
$11.9MPotential therapeutic implications of targeting miR-150 in acute myeloid leukemiaR01CA182528 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2014 to 2018
$1.7MNanoparticle formulations of DNA repair inhibitors to improve chemoradiotherapyR01CA178748 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WANG, ANDREW ZHUANG · 2013 to 2017
$1.6MDevelopment of 3D organ-specific models of colorectal cancer metastasisR21CA182322 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WANG, ANDREW ZHUANG · 2013 to 2015
$644kNCI NIH HHS P30 CA016086NCI NIH HHS R01 CA178748NCI NIH HHS R01 CA182528NCI NIH HHS R21 CA182322NCI NIH HHS U54 CA198999
Abstract
PubMed holds no abstract for this paper.
Indexed as
BiomimeticsCell MovementBiomarkersBiomarkers, TumorCase-Control StudiesCell CountCell SeparationHumansNeoplasmsNeoplastic Cells, CirculatingRadiotherapySensitivity and SpecificityTreatment OutcomeBiomarkersBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.